Nuclear survivin expression predicts poor outcome in cholangiocarcinoma

Hepato-Gastroenterology

Volumn 51, Issue 60, 2004, Pages 1653-1657

  Javle, Milind M ^a,c   Tan, Dongfeng ^b   Yu, Jihnhee ^a   LeVea, Charles M ^b   Li, Fengzhi ^b   Kuvshinoff, Boris W ^a   Gibbs, John F ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cholangiocarcinoma; Survival; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SURVIVIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; BILE DUCT NEOPLASMS; BIOPSY, NEEDLE; CHOLANGIOCARCINOMA; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 6344256319     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Yee K, Sheppard B, Domreis J, Blanke C: Cancers of the gallbladder and biliary ducts. Oncology 2002; 16:939-957.
2. Hangartner M: The biochemistry of apoptosis. Nature 2000; 407:770-776.
3. Pizem J, Cor A: Survivin, an inhibitor of apoptosis a therapeutic target in cancer. Radiol Oncol 2003; 37(3):195-201.
4. Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N, et al: Nuclear survivin in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 2004; 164(2):501-510.
5. Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H, Sunagawa M: Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003; 6(4):217-224.
6. Altura RA, Olshefski RS, Jiang Y, Bone DR: Nuclear expression of Survivin in pediatric ependymomas and choroid plexus tumours correlates with morphologic tumour grade. Br J Cancer 2003; 89(9):1743-1749.
7. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23(4):3327-3331.
8. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R: Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol 2003; 16(6):574-583.
9. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR: Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003; 29(4):379-382.
10. World Health Organization: International Classification of Diseases for Oncology (ICD-O), third edition, Geneva, Switzerland: WHO, 2000.
11. Tan D, Li Q, Ramnath N, Beck A, Wiseman S, Anderson T, Ahmad AS, Brooks J, Bepler G: Prognostic significance of expression of p53 oncoprotein in primary (Stage I-111a) non-small cell lung cancer. Anticancer Res 2003; 23:1665-1672.
12. Carriaga MT, Henson DE: Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75(Suppl 1):171-190.
13. Burke EC, Jarnagin WR, Hochwald SN, et al: Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228:385-394.
14. Anderson C, Pinson W, Berlin J, Chari R: Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9:43-57.
15. Isa T, Tomita S, Nakachi A, et al: Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology 2002; 49:604-608.
16. INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC-associated cholangiocarcinoma. Gastroenterology 2002; 123:1090-1098.
17. Harnois DM, Que FG, Celli A, et al: Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997; 26:884-890.
18. Terada T, Nakanuma Y, Sirica AE: Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998; 29:175-180.
19. Aishima SI, Taguchi KI, Sugimachi K, et al: c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. Histopathology 2002; 40:269-278.
20. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396(6711):580-584.
21. Hirokawa N: Microtubule organization and dynamics dependant on microtubule associated proteins. Curr Opin Cell Biol 1994; 6:917-921.
22. Altieri D: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7:542-547.
23. Chang Q, Liu ZR, Wang DY, Kumar M, Chen YB, Qin RY: Survivin expression induced by doxorubicin in cholangiocarcinoma. World J Gastroenterol 2004; 10(3):415-418.
24. Moon W, Tarnawski A: Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth? Human Pathol 2003; 34(11):1119-1126.
25. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Sten H, Hopfner M, Germer C, Scherubl H: Prognostic value of nuclear survivin expression in esophageal squamous cell carcinoma. Br J Cancer 2003; 88(1):115-119.
26. Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y: Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 2001; 163(1):109-116.
27. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58(9):1808-1812.
28. Wakana Y, Kasuya K, Katayanagi S, Tsuchida A, Aoki T, Koyanagi Y, Ishii H, Ebihara Y: Effect of survivin on cell proliferation and apoptosis in gastric cancer. Oncol Rep 2002; 9(6):1213-1218.
29. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, Tognin S, Marchisio PC, Altieri DC: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115(Pt 3):575-585.
30. Mahotka C, Liebmann J, Wenzel M, Suschek C, Schmitt M, Gabbert H, Gerharz C: Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Different 2002; 9:1334-1342.
31. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M: Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun 2004; 314(3):902-907.
32. Bhargava P, Jani CR, Savarese DM, O'Donnell JL, Stuart KE, Rocha Lima CM: Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncology (Huntingt) 2003; 17(9 Suppl 8):23-26.
33. Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I: Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5fluorouracil for biliary tract cancer. Clin Cancer Res 2001; 7(11):3375-3380.
34. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, Lenauer J, Brodowicz T, Lang F, Scheithauer W: Two consecutive phase II studies of 5-fluorouracillleucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999; 56(3):177-180.
35. Yeh C, Jan Y, Chen M: The influence of age on surgical treatment of peripheral cholangiocarcinoma. Am J Surg 2004; 187:559-563.
36. Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J: Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis. Hepatogastroenterology 2002; 49(4):311-316.
37. Yang JH, Zhang YC, Qian HQ: Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells. World J Gastroenterol 2004; 10(8):1121-1124.
38. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M: Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2003; 2(5):488-493.